Abstract

Background. Microbiologic confirmation of respiratory tract infections gained importance during the coronavirus disease 2019 (COVID-19) pandemic. This study retrospectively evaluated seasonal distribution, clinical presentation, and complications of respiratory viral infections (RVIs) other than COVID-19 in children with cancer during and after the pandemic lockdown.

Methods. Two hundred and sixty-five inpatient and outpatient RVI episodes in 219 pediatric cancer patients confirmed by multiplex reverse transcriptase polymerase chain reaction (RT-PCR) panels from 13 centers were enrolled.

Results. Eighty-six (32.5%) of the total 265 episodes occurred in 16 months corresponding to the lockdowns in Türkiye, and the remaining 67.5% in 10 months thereafter. Human rhinovirus/enterovirus (hRE) (48.3%) was the most common agent detected during and after lockdown. Parainfluenza virus (PIV) (23.0%), influenza virus (9.8%), and respiratory syncytial virus (RSV) (9.1%) were the other common agents. The 28.7% of episodes were lower respiratory tract infections (LRTIs), and complications and mortality were higher than upper respiratory tract infections (URTIs) (25.0% vs 5.3%). Bacteremia was identified in 11.5% of culture-drawn episodes. Treatment delay in one-third and death within four weeks after RVI in 4.9% of episodes were observed.

Conclusion. During the pandemic, fewer episodes of RVIs occurred during the lockdown period. Respiratory viruses may cause complications, delays in treatment, and even death in children with cancer. Therefore, increased awareness of RVIs and rapid detection of respiratory viruses will benefit the prevention and, in some cases, abrupt supportive and some antiviral treatment of RVI in children with cancer. 

Keywords: respiratory viral infections, children, cancer, COVID-19

Copyright and license

Copyright © 2024 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Kaçar D, Kebudi R, Özyörük D, et al. Common viral respiratory infections in children with cancer during the COVID-19 pandemic: a multicenter study from Türkiye. Turk J Pediatr 2024; 66: 401-411. https://doi.org/10.24953/turkjpediatr.2024.4536

References

  1. Hijano DR, Maron G, Hayden RT. Respiratory viral infections in patients with cancer or undergoing hematopoietic cell transplant. Front Microbiol 2018; 9: 3097. https://doi.org/10.3389/fmicb.2018.03097
  2. Kebudi R, Kurucu N, Tuğcu D, et al. COVID-19 infection in children with cancer and stem cell transplant recipients in Turkey: a nationwide study. Pediatr Blood Cancer 2021; 68: e28915. https://doi.org/10.1002/pbc.28915
  3. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 2011; 52: e56-e93. https://doi.org/10.1093/cid/cir073
  4. Gabutti G, De Motoli F, Sandri F, Toffoletto MV, Stefanati A. Viral respiratory infections in hematological patients. Infect Dis Ther 2020; 9: 495-510. https://doi.org/10.1007/s40121-020-00313-6
  5. Nagakubo Y, Hirotsu Y, Maejima M, et al. Non-pharmaceutical interventions during the COVID-19 epidemic changed detection rates of other circulating respiratory pathogens in Japan. PLoS One 2022; 17: e0262874. https://doi.org/10.1371/journal.pone.0262874
  6. Büyükkapu-Bay S, Kebudi R, Görgün Ö, Meşe S, Zülfikar B, Badur S. Respiratory viral infection`s frequency and clinical outcome in symptomatic children with cancer: a single center experience from a middle-income country. Turk J Pediatr 2018; 60: 653-659. https://doi.org/10.24953/turkjped.2018.06.005
  7. Aydin Köker S, Demirağ B, Tahta N, et al. A 3-year retrospective study of the epidemiology of acute respiratory viral infections in pediatric patients with cancer undergoing chemotherapy. J Pediatr Hematol Oncol 2019; 41: e242-e246. https://doi.org/10.1097/MPH.0000000000001418
  8. Yiğit M, Özkaya Parlakay A. Decreased pediatric viral burden and increased rhinovirus infection during the COVID-19 pandemic. Turk J Pediatr Dis 2022; 16: 395-401. https://doi.org/10.12956/tchd.1026670
  9. Srinivasan A, Gu Z, Smith T, et al. Prospective detection of respiratory pathogens in symptomatic children with cancer. Pediatr Infect Dis J 2013; 32: e99-e104. https://doi.org/10.1097/INF.0b013e31827bd619
  10. Maeng SH, Yoo HS, Choi SH, et al. Impact of parainfluenza virus infection in pediatric cancer patients. Pediatr Blood Cancer 2012; 59: 708-710. https://doi.org/10.1002/pbc.23390
  11. Lefeuvre C, Salmona M, Bondeelle L, et al. Frequent lower respiratory tract disease in hematological patients with parainfluenza virus type 3 infection. J Med Virol 2021; 93: 6371-6376. https://doi.org/10.1002/jmv.27243
  12. Fisher BT, Danziger-Isakov L, Sweet LR, et al. A multicenter consortium to define the epidemiology and outcomes of inpatient respiratory viral infections in pediatric hematopoietic stem cell transplant recipients. J Pediatric Infect Dis Soc 2018; 7: 275-282. https://doi.org/10.1093/jpids/pix051
  13. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011; 117: 2755-2763. https://doi.org/10.1182/blood-2010-08-263400
  14. Ali S, Krueger J, Richardson SE, et al. The yield of monitoring adenovirus in pediatric hematopoietic stem cell transplant patients. Pediatr Hematol Oncol 2019; 36: 161-172. https://doi.org/10.1080/08880018.2019.1607961
  15. Akturk H, Sık G, Salman N, et al. Atypical presentation of human bocavirus: severe respiratory tract infection complicated with encephalopathy. J Med Virol 2015; 87: 1831-1838. https://doi.org/10.1002/jmv.24263
  16. Ogimi C, Martin ET, Xie H, et al. Role of human bocavirus respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2021; 73: e4392-e4399. https://doi.org/10.1093/cid/ciaa1149
  17. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58: e44-100. https://doi.org/10.1093/cid/cit684
  18. Meena JP, Brijwal M, Seth R, et al. Prevalence and clinical outcome of respiratory viral infections among children with cancer and febrile neutropenia. Pediatr Hematol Oncol 2019; 36: 330-343. https://doi.org/10.1080/08880018.2019.1631920
  19. Koskenvuo M, Möttönen M, Rahiala J, et al. Mixed bacterial-viral infections in septic children with leukemia. Pediatr Infect Dis J 2007; 26: 1133-1136. https://doi.org/10.1097/INF.0b013e318146207c
  20. Shinn K, Wetzel M, DeGroote NP, et al. Impact of respiratory viral panel testing on length of stay in pediatric cancer patients admitted with fever and neutropenia. Pediatr Blood Cancer 2020; 67: e28570. https://doi.org/10.1002/pbc.28570
  21. Alali M, David MZ, Danziger-Isakov LA, Elmuti L, Bhagat PH, Bartlett AH. Pediatric febrile neutropenia: change in etiology of bacteremia, empiric choice of therapy and clinical outcomes. J Pediatr Hematol Oncol 2020; 42: e445-e451. https://doi.org/10.1097/MPH.0000000000001814
  22. Kara SS, Tezer H, Polat M, et al. Risk factors for bacteremia in children with febrile neutropenia. Turk J Med Sci 2019; 49: 1198-1205. https://doi.org/10.3906/sag-1901-90
  23. Haeusler GM, Thursky KA, Slavin MA, et al. Risk stratification in children with cancer and febrile neutropenia: a national, prospective, multicentre validation of nine clinical decision rules. EClinicalMedicine 2020; 18: 100220. https://doi.org/10.1016/j.eclinm.2019.11.013
  24. Neuman MI, Hall M, Lipsett SC, et al. Utility of blood culture among children hospitalized with community-acquired pneumonia. Pediatrics 2017; 140: e20171013. https://doi.org/10.1542/peds.2017-1013
  25. Youssef AS, Fanous M, Siddiqui FJ, et al. Value of blood cultures in the management of children hospitalized with community-acquired pneumonia. Cureus 2020; 12: e8222. https://doi.org/10.7759/cureus.8222
  26. Fritz CQ, Edwards KM, Self WH, et al. Prevalence, risk factors, and outcomes of bacteremic pneumonia in children. Pediatrics 2019; 144: e20183090. https://doi.org/10.1542/peds.2018-3090
  27. Hakim H, Dallas R, Zhou Y, et al. Acute respiratory infections in children and adolescents with acute lymphoblastic leukemia. Cancer 2016; 122: 798-805. https://doi.org/10.1002/cncr.29833
  28. Marinelli T, Wee LYA, Rowe E, et al. Respiratory viruses cause late morbidity in recipients of hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2020; 26: 782-788. https://doi.org/10.1016/j.bbmt.2019.12.724
  29. Damlaj M, Bartoo G, Cartin-Ceba R, et al. Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients. Transpl Infect Dis 2016; 18: 216-226. https://doi.org/10.1111/tid.12513
  30. Pochon C, Voigt S. Respiratory virus infections in hematopoietic cell transplant recipients. Front Microbiol 2019; 9: 3294. https://doi.org/10.3389/fmicb.2018.03294
  31. Prasso JE, Deng JC. Postviral complications: bacterial peumonia. Clin Chest Med 2017; 38: 127-138. https://doi.org/10.1016/j.ccm.2016.11.006
  32. Peltola V, Heikkinen T, Ruuskanen O, et al. Temporal association between rhinovirus circulation in the community and invasive pneumococcal disease in children. Pediatr Infect Dis J 2011; 30: 456-461. https://doi.org/10.1097/INF.0b013e318208ee82
  33. Dror T, Akerman M, Noor A, Weinblatt ME, Islam S, Glasser CL. Seasonal variation of respiratory viral infections: a comparative study between children with cancer undergoing chemotherapy and children without cancer. Pediatr Hematol Oncol 2021; 38: 444-455. https://doi.org/10.1080/08880018.2020.1871137